Compare LODE & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | KRRO |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 187.9M |
| IPO Year | 2004 | 2019 |
| Metric | LODE | KRRO |
|---|---|---|
| Price | $3.44 | $13.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $4.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 1.4M | 128.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,553,796.00 | ★ $6,392,000.00 |
| Revenue This Year | $1,582.85 | N/A |
| Revenue Next Year | $246.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $2.24 | $5.20 |
| 52 Week High | $4.98 | $55.89 |
| Indicator | LODE | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 60.71 |
| Support Level | $3.02 | $9.76 |
| Resistance Level | $3.68 | $14.53 |
| Average True Range (ATR) | 0.22 | 0.78 |
| MACD | 0.07 | 0.32 |
| Stochastic Oscillator | 78.22 | 83.25 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.